Joseph A. Sparano was named chief of hematology and medical oncology and deputy director of The Tisch Cancer Institute of Mount Sinai Health System.
Edward Kim was named medical director for the Office of Clinical Research at UC Davis Comprehensive Cancer Center, effective July 1.
David Klimstra was named chief medical officer of Paige, effective August 2021.
Bridget F. Koontz was named U.S. chief medical officer of the Deputy Group and Neal D. Shore was named U.S. chief medical officer of surgery and urology at GenesisCare.
Friends of Cancer Research has launched Step 2 of the ctDNA for Monitoring Treatment Response (ctMoniTR) Project.
City of Hope and ProBioGen AG have entered into a commercial product license agreement, which grants City of Hope the rights to use ProBioGen’s cell line AGE1.CR.pIX for manufacturing City of Hope’s COVID-19 vaccine candidate.
A study found that PD-L1, PD-L2 and tumor mutation burden from a comprehensive genomic and transcriptomic profiling test independently predicted Keytruda (pembrolizumab) benefit in pan-solid tumors—and when combined in a multivariate signature score—predicted benefit better than PD-L1 or TMB alone.
The phase III TULIP study met its primary endpoint of progression-free survival in patients with pretreated HER2-positive unresectable locally advanced or metastatic breast cancer—demonstrating a statistically significant improvement over physician’s choice.
The likelihood of prostate cancer surgery for patients presenting for treatment across Pennsylvania declined among Black patients, but not white patients, during the initial wave of the COVID-19 pandemic, according to new research from Fox Chase Cancer Center.
Roswell Park Comprehensive Cancer Center researchers found that an opioid-restricting protocol resulted in a 45% decrease in the amount of opioids prescribed, without any significant effect on patient recovery or satisfaction.
